Carpinteria, CA June 2, 2008 -- NuSil Technology, a cutting-edge manufacturer of silicone compounds for the healthcare, drug delivery and pharmaceutical industries, announced the completion of a study in hydrophilic silicone formulations. The results of the study were presented at the 2008 World Biomaterials Congress and demonstrate the company's commitment to expand and create innovative products for the medical device and drug delivery market.

In 2007, NuSil launched a multiphase study to demonstrate the effects of modifying silicone polymers with hydrophilic groups. The first phase illustrated how variations in silicone chemistry can influence its compatibility with the surrounding environment. The second phase expands on the initial findings. In addition to the Biomaterials Conference, the company plans to discuss this research at Medical Design & Manufacturing East in New York, June 3-5. Customers interested in learning more about this effort can visit www.nusil.com/products/healthcare/drug_delivery.

"NuSil Technology is continuing to support the medical device and pharmaceutical industry with research in hydrophilic silicone chemistries," said Brian Nash, vice president of Marketing and Sales. "We want to show our customers NuSil's commitment to designing products that meet the needs of an individual medical device or drug delivery system."

About NuSil Silicone Technology
NuSil is a cutting-edge manufacturer of silicone compounds for healthcare, aerospace, electronics, photonics and other applications requiring precise, predictable, cost-effective materials performance. ISO-9001 certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and Europe and provides on-site, in-person application engineering support worldwide. More information about NuSil Technology can be found at www.nusil.com.